Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Neutral

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Strong Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Armata Pharmaceuticals, Inc. Common Stock (ARMP)

Biological Products, (no Disgnostic Substances)

https://www.armatapharma.com

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

4503 GLENCOE AVENUE
MARINA DEL REY, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/27/1994

Market Cap

91,181,412

Shares Outstanding

36,150,000

Weighted SO

36,146,574

Total Employees

N/A

Upcoming Earnings

08/12/2024

Similar Tickers

ARAV --.--%

ARDS --.--%

ANIX --.--%

PHGE --.--%

ALPN --.--%

Beta

0.7630

Last Div

0.0000

Range

1.9-4.48

Chg

0.0800

Avg Vol

10124

Mkt Cap

91181412

Exch

AMEX

Country

US

Phone

858 829 0829

DCF Diff

3.6331

DCF

-0.0030

Div Yield

0.0000

P/S

24.5177

EV Multiple

-3.7201

P/FV

-1.9763

Div Yield %

0.0000

P/E

-1.3590

PEG

-0.0516

Payout

0.0000

Current Ratio

0.2509

Quick Ratio

0.2509

Cash Ratio

0.2144

DSO

121.8957

DIO

0.0000

Op Cycle

121.8957

DPO

555.1440

CCC

-433.2483

Gross Margin

0.6919

Op Margin

-11.3087

Pretax Margin

-18.0272

Net Margin

-18.0272

Eff Tax Rate

-0.0506

ROA

-0.6190

ROE

1.8235

ROCE

2.8287

NI/EBT

1.0000

EBT/EBIT

1.5941

EBIT/Rev

-11.3087

Debt Ratio

1.3492

D/E

-3.1700

LT Debt/Cap

-1.5690

Total Debt/Cap

1.4608

Int Coverage

-24.3385

CF/Debt

-0.2638

Equity Multi

-2.3495

Rec Turnover

2.9944

Pay Turnover

0.6575

Inv Turnover

0.0000

FA Turnover

0.0651

Asset Turnover

0.0343

OCF/Share

-1.0664

FCF/Share

-1.2746

Cash/Share

0.7303

OCF/Sales

-10.3668

FCF/OCF

1.1953

CF Coverage

-0.2638

ST Coverage

-0.3268

CapEx Coverage

-5.1214

Div&CapEx Cov

-5.1214

P/BV

-1.9763

P/B

-1.9763

P/S

24.5177

P/E

-1.3590

P/FCF

-1.9787

P/OCF

-2.3632

P/CF

-2.3632

PEG

-0.0516

P/S

24.5177

EV Multiple

-3.7201

P/FV

-1.9763

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 28, 15:57 Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report

Revenue Product Segmentation